Pay in 4 interest-free payments of $30.00 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
121345-64-0
(R)-(-)-Ibuprofen inhibits NF-κB luciferase activity with an IC50 of 121
Smiles: CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C
The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline
LP-261 - CAS# 915412-67-8 Size:2mg solid 121345-64-0LP 261 is a novel tubulin targeting anticancer agent that binds at the colchicine site on tubulin, inducing G2 M arrest. Screening in the NCI60 cancer cell lines resulted in a mean GI50 of approximately 100 nM. LP 261 is a very potent inhibitor of angiogenesis, preventing microvessel outgrowth in the rat aortic ring assay and HUVEC cell proliferation at nanomolar concentrations. Complete inhibition of tumor growth was achieved in the PC3 xenograft
US$ 169.00
US$ 65.00
US$ 77.00
US$ 35.95
US$ 271.50
US$ 149.00